RXDX - Prometheus Biosciences, Inc. Stock Price and Quote

RXDX [NASD]

Index	-	P/E	-	EPS (ttm)	-3.35	Insider Own	0.20%	Shs Outstand	41.22M	Perf Week	-0.92%
Market Cap	5.25B	Forward P/E	-	EPS next Y	-3.62	Insider Trans	-24.70%	Shs Float	37.38M	Perf Month	5.17%
Income	-132.90M	PEG	-	EPS next Q	-0.91	Inst Own	72.70%	Short Float / Ratio	10.33% / 4.29	Perf Quarter	114.36%
Sales	7.20M	P/S	728.95	EPS this Y	-244.40%	Inst Trans	8.73%	Short Interest	3.86M	Perf Half Y	168.97%
Book/sh	5.64	P/B	20.35	EPS next Y	-4.60%	ROA	-50.30%	Target Price	146.18	Perf Year	248.84%
Cash/sh	5.69	P/C	20.17	EPS next 5Y	-	ROE	-61.40%	52W Range	21.50 - 122.75	Perf YTD	4.34%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-6.50%	Beta	-
Dividend %	-	Quick Ratio	11.20	Sales past 5Y	-	Gross Margin	-	52W Low	433.81%	ATR	5.30
Employees	72	Current Ratio	11.20	Sales Q/Q	0.00%	Oper. Margin	-	RSI (14)	58.47	Volatility	4.59% 4.45%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-28.50%	Profit Margin	-	Rel Volume	0.52	Prev Close	116.12
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	899.94K	Price	114.77
Recom	1.50	SMA20	1.07%	SMA50	26.29%	SMA200	116.59%	Volume	465,041	Change	-1.16%

Jul-20-22

Initiated

Goldman

Buy

$51

Jun-10-22

Initiated

Piper Sandler

Overweight

$53

Feb-11-22

Initiated

BTIG Research

Buy

$62

Dec-13-21

Initiated

RBC Capital Mkts

Outperform

$46

Dec-08-21

Upgrade

Oppenheimer

Perform → Outperform

$35 → $50

Dec-08-21

Initiated

Wells Fargo

Overweight

$42

Nov-15-21

Downgrade

Oppenheimer

Outperform → Perform

$35

Nov-12-21

Resumed

Stifel

Buy

$45

Oct-05-21

Initiated

Oppenheimer

Outperform

$35

Apr-26-21

Resumed

Credit Suisse

Outperform

$30

Show Previous Ratings

Jan-16-23 07:42AM	Zacks Investment Ideas feature highlights: XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB Zacks
Jan-13-23 12:32PM	Biotech's Blockbuster Week: 3 Stocks to Watch Zacks
Jan-10-23 09:55AM	Wall Street Analysts Believe Prometheus Biosciences, Inc. (RXDX) Could Rally 26.51%: Here's is How to Trade Zacks
Jan-03-23 08:30AM	Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-23-22 07:02AM	We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash Wisely Simply Wall St.
03:02PM	Loading…
Dec-13-22 03:02PM	12 Best Multibagger Stocks to Buy Now Insider Monkey
Dec-09-22 05:32AM	Is Prometheus Biosciences a Good Stock to Buy Right Now? Motley Fool -5.98%
Dec-08-22 07:39PM	Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock GlobeNewswire +22.35%
12:12PM	Why Shares of Prometheus Biosciences Are Soaring This Week Motley Fool
Dec-07-22 04:13PM	Prometheus Bio 'Comfortably Overshoots' Drug's Expectations And Shares Nearly Triple Investor's Business Daily +165.67%
04:01PM	Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
12:16PM	2 Biotech Stocks Options Traders Love Today Schaeffer's Investment Research
08:31AM	Prometheus shares rally 177% as it prepares to move drug into Phase 3 studies MarketWatch
08:29AM	These 2 Nasdaq Stocks Knocked It Out of the Park Wednesday Motley Fool
07:00AM	Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb GlobeNewswire
11:48AM	Loading…
Dec-02-22 11:48AM	Why Shares of Prometheus Biosciences Slumped This Week Motley Fool
Nov-12-22 07:52AM	Prometheus Biosciences Third Quarter 2022 Earnings: Beats Expectations Simply Wall St.
Nov-09-22 05:25PM	Prometheus Biosciences, Inc. (RXDX) Reports Q3 Loss, Tops Revenue Estimates Zacks +5.57%
04:01PM	Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress GlobeNewswire
Nov-01-22 08:00AM	Prometheus Biosciences to Participate at November Healthcare Conferences GlobeNewswire
Oct-12-22 07:54AM	Prometheus Biosciences (NASDAQ:RXDX) pulls back 15% this week, but still delivers shareholders splendid 103% return over 1 year Simply Wall St.
Oct-03-22 08:30AM	Prometheus Biosciences Receives FDA Clearance of IND Application for its Second Precision Program, PRA052 GlobeNewswire
Sep-20-22 05:31AM	Can This Tiny Biotech Take On Pfizer? Motley Fool
Sep-15-22 03:00PM	7 Top-Rated Biotech Stocks to Buy for Q4 InvestorPlace
Sep-08-22 11:14AM	12 Best IPO Stocks to Invest In Right Now Insider Monkey
Aug-31-22 04:00PM	Prometheus Biosciences to Participate at September Healthcare Conferences GlobeNewswire
Aug-29-22 12:00PM	What Makes Prometheus Biosciences, Inc. (RXDX) a New Buy Stock Zacks
Aug-11-22 05:15PM	Prometheus Biosciences, Inc. (RXDX) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:00PM	Prometheus Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress GlobeNewswire
Jul-24-22 05:04AM	Buy These 2 Stocks Before They Jump Over 40%, Says Goldman Sachs TipRanks
04:00PM	Loading…
Jul-18-22 04:00PM	Prometheus Biosciences to Host a Virtual R&D Day for Analysts and Investors on July 26, 2022 GlobeNewswire
08:00AM	Prometheus Biosciences Completes Enrollment of the ARTEMIS-UC Cohort 1 Phase 2 Study in Ulcerative Colitis GlobeNewswire
Jul-14-22 02:41PM	Prometheus Biosciences Stock Shows Rising Relative Strength Investor's Business Daily
Jun-22-22 09:54AM	Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation Simply Wall St.
Jun-08-22 08:00AM	Prometheus Biosciences Provides Enrollment Update in APOLLO-CD and ARTEMIS-UC Global Phase 2 Studies GlobeNewswire
May-26-22 08:00AM	Prometheus Biosciences to Participate at the Jefferies Healthcare Conference GlobeNewswire
May-12-22 05:15PM	Prometheus Biosciences, Inc. (RXDX) Reports Q1 Loss, Tops Revenue Estimates Zacks +5.27%
04:01PM	Prometheus Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress GlobeNewswire
May-05-22 07:23AM	Prometheus Biosciences (NASDAQ:RXDX) delivers shareholders decent 43% return over 1 year, surging 20% in the last week alone Simply Wall St. -8.68%
Mar-30-22 08:00AM	Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) GlobeNewswire
Mar-09-22 04:01PM	Prometheus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Progress GlobeNewswire +11.16%
Mar-01-22 08:30AM	Prometheus Biosciences to Participate at the Cowen 42nd Annual Healthcare Conference GlobeNewswire
Feb-07-22 05:38PM	Ar Asset Management Inc Buys Organon, Prometheus Biosciences Inc, Prometheus Biosciences Inc, ... GuruFocus.com +9.74%
08:00AM	Prometheus Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Jan-19-22 04:30AM	5 Biotech Stocks That Are Bucking the Selloff Barrons.com
Jan-12-22 08:30AM	Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire -8.69%
Jan-05-22 08:30AM	Prometheus Biosciences to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference GlobeNewswire -6.39%
Jan-03-22 08:00AM	Prometheus Biosciences and Dr. Falk Pharma Advance PR600 and Trigger Final Preclinical Milestone Payment GlobeNewswire
Dec-13-21 12:50PM	Prometheus Biosciences (NASDAQ:RXDX) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Dec-07-21 07:00AM	Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) GlobeNewswire +7.32%
Nov-12-21 08:00AM	Prometheus Biosciences Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Progress GlobeNewswire
Nov-02-21 08:00AM	Prometheus Biosciences to Present at Upcoming Investor Conferences GlobeNewswire +5.43%
Oct-12-21 04:01PM	Prometheus Biosciences to Present at Jefferies Virtual Next Generation IBD Therapeutics Summit GlobeNewswire
Oct-06-21 06:13AM	10 Small-Cap Stocks to Buy According to Australias Warren Buffett Kerr Neilson Insider Monkey
Aug-13-21 05:06AM	Prometheus Biosciences, Inc. (NASDAQ:RXDX) insiders have profited after buying stock worth US$561k last year, current gains stand at US$82k Simply Wall St. +5.60%
Aug-11-21 04:01PM	Prometheus Biosciences Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Progress GlobeNewswire -6.56%
Aug-05-21 07:30AM	In Memoriam Friend, Scientific Innovator, Advisor and Board Chair Dr. Tadataka Yamada Has Passed Away GlobeNewswire +5.59%
Aug-02-21 08:00AM	Prometheus Biosciences Announces Initiation of APOLLO-CD Phase 2a Clinical Trial of PRA023 in Moderate-to-Severe Crohns Disease GlobeNewswire
Jul-19-21 12:50PM	Should I Buy Prometheus Biosciences, Inc. (RXDX)? Insider Monkey
08:00AM	Prometheus Biosciences Announces Initiation of Global Phase 2 Clinical Trial of PRA023 in Moderate-to-Severe Ulcerative Colitis (UC) GlobeNewswire
Jul-15-21 08:00AM	Prometheus Biosciences to Host Virtual R&D Day for Investors on July 28, 2021 GlobeNewswire
Jun-21-21 09:00AM	Prometheus Biosciences Achieves Milestone Payment from Dr. Falk Pharma GmbH Further Validating the Prometheus360 Platform GlobeNewswire
Jun-14-21 06:59AM	How Many Prometheus Biosciences, Inc. (NASDAQ:RXDX) Shares Do Institutions Own? Simply Wall St. +9.66%
May-25-21 04:05PM	Prometheus Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference GlobeNewswire
May-17-21 08:00AM	Fred Hassan, Former CEO of Schering-Plough and Former Chairman of Bausch & Lomb, Joins Prometheus Biosciences Board GlobeNewswire +21.76%
May-14-21 04:01PM	Prometheus Biosciences to Present at 2021 RBC Capital Markets Global Healthcare Conference GlobeNewswire
May-13-21 04:01PM	Prometheus Biosciences Reports First Quarter 2021 Financial Results and Provides a Corporate Update GlobeNewswire -5.56%
Apr-07-21 10:34AM	Buy These 2 Stocks Before They Jump 80%, Say Analysts TipRanks
Mar-16-21 04:05PM	Prometheus Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire -8.00%
Mar-11-21 10:26PM	Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering PR Newswire

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Marshall Keith W	Chief Financial Officer	Jan 17	Option Exercise	3.70	5,000	18,500	14,811	Jan 19 08:42 PM
McKenna Mark C.	Chairman, President & CEO	Jan 17	Option Exercise	2.90	25,000	72,500	80,144	Jan 19 08:39 PM
Marshall Keith W	Chief Financial Officer	Jan 17	Sale	119.00	5,000	595,000	9,811	Jan 19 08:42 PM
McKenna Mark C.	Chairman, President & CEO	Jan 17	Sale	118.99	25,000	2,974,750	55,144	Jan 19 08:39 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience